The Experts below are selected from a list of 34725 Experts worldwide ranked by ideXlab platform

Titania Pasqualini - One of the best experts on this subject based on the ideXlab platform.

  • effect of deflazacort versus methylprednisone on growth body composition lipid profile and bone mass after renal transplantation
    Pediatric Nephrology, 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P<0.05) and decreased in deflazacort-treated patients (P<0.005). Lean body mass increased in both groups (P<0.005). Fat body mass and serum leptin increased only in methylprednisone-treated patients (P<0.025). Total cholesterol and low-density lipoprotein-cholesterol increased in methylprednisone-treated patients by 9.9% (P<0.05) and 12.5% (P<0.025). High-density lipoprotein-cholesterol increased by 21% (P<0.005) and apolipoprotein B decreased by 11% (P<0.005) in deflazacort-treated patients. Total skeleton and lumbar spine bone mineral density decreased in both groups, but at 1 year methylprednisone-treated patients had lost 50% more bone. Bone mineral content decreased only in methylprednisone-treated patients (P<0.01). Our data suggest that substituting deflazacort for maintenance methylprednisone might prevent Height loss, excessive bone loss, and fat accumulation; and leads to an improvement in the lipoproteins of these children.

  • Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation
    Pediatric nephrology (Berlin Germany), 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Héctor G. Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P

  • Effect of therapy with deflazacort on dyslipoproteinemia after pediatric renal transplantation.
    The Journal of Pediatrics, 1998
    Co-Authors: Jorge R Ferraris, Patricia Sorroche, José Oyhamburu, Pedro Brandi, Titania Pasqualini
    Abstract:

    Deflazacort is an oxazolone compound derived from prednisolone, with similar immunosuppressive action but fewer side effects. Kidney function, Weight/Height Ratio, serum triglycerides, cholesterol, high-density lipoprotein (HDL) cholesterol, very-low-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein A, apolipoprotein B, and lipoprotein (a) were studied before and 6 months after substitution of deflazacort (mean ± SEM, 0.3 ± 0.1 mg/kg per day) for methylprednisone (0.2 ± 0.1 mg/kg per day) in 14 patients treated with cyclosporine, aged 3.1 to 20.3 years, 3 years after renal transplantation. Serum creatinine and calculated creatinine clearance did not change significantly, and Weight/Height Ratio decreased from 20.0% ± 7.1% to 12.5% ± 6.5% (P < .005) during deflazacort therapy. Total cholesterol was reduced by 15.9% (from 233 ± 15 mg/dL to 196 ± 13 mg/dL, P < .01), LDL cholesterol by 25.5% (from 153 ± 14 mg/dL to 114 ± 12 mg/dL, P < .01), and TC/HDL cholesterol Ratio by 28.3% (from 5.3 ± 0.4 to 3.8 ± 0.4, P < .01), whereas HDL cholesterol increased 18% (from 45 ± 2 mg/dL to 53 ± 2 mg/dL) and apolipoprotein A by 8.3% (from 122 ± 5 mg/dL to 132 ± 5 mg/dL, P < .05) during deflazacort therapy. Our data suggest that substituting deflazacort for maintenance methylprednisone therapy leads to an improvement in the lipoprotein profile of children after renal transplantation. (J Pediatr 1998;133:533-6)

  • effects of deflazacort immunosuppression on long term growth and growth factors after renal transplantation
    Pediatric Nephrology, 1997
    Co-Authors: Jorge R Ferraris, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Deflazacort is an oxazoline compound derived from prednisolone. We studied changes in kidney function, growth velocity, Weight/Height Ratio, insulin-like growth factor (IGF-I), and IGF binding proteins before and after substitution of deflazacort for methylprednisone in 27 transplanted patients aged 3.1 – 20 years. Methylprednisone (mean±SEM 0.17±0.01 mg/kg per day) was replaced by deflazacort (0.29±0.01 mg/kg per day) for a period of 1 – 5 years. Calculated creatinine clearance did not change significantly during deflazacort treatment. Growth velocity increased from 2.6±0.5 cm/year to 5.2±0.7 cm/year (1st year) in 14 prepubertal patients. After 4 years of deflazacort treatment, Height standard deviation score for chronological age did not change in 7 prepubertal patients. Mean Weight/Height Ratio decreased by 50% (1st year) and remained reduced during follow-up. Serum IGF-I, IGF binding protein -3 (IGFBP3), IGF/IGFBP3 molar Ratio, and IGF-I and -II binding capacities showed no significant change; however in 5 of 6 patients IGFBP2 decreased during deflazacort therapy. Our findings suggest that immunosuppressive treatment with deflazacort is as effective as methylprednisone and may lead to an improvement in the growth prognosis of children with renal transplantation.

  • effect of therapy with a new glucocorticoid deflazacort on linear growth and growth hormone secretion after renal transplantation
    The Journal of Pediatrics, 1992
    Co-Authors: Jorge R Ferraris, Raul Gutman, E Granillo, Susana Ruiz, José A. Ramírez, Titania Pasqualini
    Abstract:

    Deflazacort is an oxazoline compound derived from prednisolone with similar antiinflammatory effects but fewer side effects. We studied changes in kidney function, growth velocity, Weight/Height Ratio, and growth hormone secretion before and a year after substitution of deflazacort for methylprednisone in nine patients aged 9 to 15 years, 4 years after renal transplantation; all were in Taner pubertal stage 1. Methylprednisone (mean±SEM: 0.2±0.02 mg/kg per day) was replaced by deflazacort (0.3±0.03 mg/kg per day) for a mean period of 15 months. Serum creatinine and calculated creatinine clearance did not change significantly during deflazacort treatment. Growth velocity increased from 1.5±0.3 to 3.2±0.5 cm/yr ( p p p

Jorge R Ferraris - One of the best experts on this subject based on the ideXlab platform.

  • effect of deflazacort versus methylprednisone on growth body composition lipid profile and bone mass after renal transplantation
    Pediatric Nephrology, 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P<0.05) and decreased in deflazacort-treated patients (P<0.005). Lean body mass increased in both groups (P<0.005). Fat body mass and serum leptin increased only in methylprednisone-treated patients (P<0.025). Total cholesterol and low-density lipoprotein-cholesterol increased in methylprednisone-treated patients by 9.9% (P<0.05) and 12.5% (P<0.025). High-density lipoprotein-cholesterol increased by 21% (P<0.005) and apolipoprotein B decreased by 11% (P<0.005) in deflazacort-treated patients. Total skeleton and lumbar spine bone mineral density decreased in both groups, but at 1 year methylprednisone-treated patients had lost 50% more bone. Bone mineral content decreased only in methylprednisone-treated patients (P<0.01). Our data suggest that substituting deflazacort for maintenance methylprednisone might prevent Height loss, excessive bone loss, and fat accumulation; and leads to an improvement in the lipoproteins of these children.

  • Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation
    Pediatric nephrology (Berlin Germany), 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Héctor G. Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P

  • Effect of therapy with deflazacort on dyslipoproteinemia after pediatric renal transplantation.
    The Journal of Pediatrics, 1998
    Co-Authors: Jorge R Ferraris, Patricia Sorroche, José Oyhamburu, Pedro Brandi, Titania Pasqualini
    Abstract:

    Deflazacort is an oxazolone compound derived from prednisolone, with similar immunosuppressive action but fewer side effects. Kidney function, Weight/Height Ratio, serum triglycerides, cholesterol, high-density lipoprotein (HDL) cholesterol, very-low-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein A, apolipoprotein B, and lipoprotein (a) were studied before and 6 months after substitution of deflazacort (mean ± SEM, 0.3 ± 0.1 mg/kg per day) for methylprednisone (0.2 ± 0.1 mg/kg per day) in 14 patients treated with cyclosporine, aged 3.1 to 20.3 years, 3 years after renal transplantation. Serum creatinine and calculated creatinine clearance did not change significantly, and Weight/Height Ratio decreased from 20.0% ± 7.1% to 12.5% ± 6.5% (P < .005) during deflazacort therapy. Total cholesterol was reduced by 15.9% (from 233 ± 15 mg/dL to 196 ± 13 mg/dL, P < .01), LDL cholesterol by 25.5% (from 153 ± 14 mg/dL to 114 ± 12 mg/dL, P < .01), and TC/HDL cholesterol Ratio by 28.3% (from 5.3 ± 0.4 to 3.8 ± 0.4, P < .01), whereas HDL cholesterol increased 18% (from 45 ± 2 mg/dL to 53 ± 2 mg/dL) and apolipoprotein A by 8.3% (from 122 ± 5 mg/dL to 132 ± 5 mg/dL, P < .05) during deflazacort therapy. Our data suggest that substituting deflazacort for maintenance methylprednisone therapy leads to an improvement in the lipoprotein profile of children after renal transplantation. (J Pediatr 1998;133:533-6)

  • effects of deflazacort immunosuppression on long term growth and growth factors after renal transplantation
    Pediatric Nephrology, 1997
    Co-Authors: Jorge R Ferraris, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Deflazacort is an oxazoline compound derived from prednisolone. We studied changes in kidney function, growth velocity, Weight/Height Ratio, insulin-like growth factor (IGF-I), and IGF binding proteins before and after substitution of deflazacort for methylprednisone in 27 transplanted patients aged 3.1 – 20 years. Methylprednisone (mean±SEM 0.17±0.01 mg/kg per day) was replaced by deflazacort (0.29±0.01 mg/kg per day) for a period of 1 – 5 years. Calculated creatinine clearance did not change significantly during deflazacort treatment. Growth velocity increased from 2.6±0.5 cm/year to 5.2±0.7 cm/year (1st year) in 14 prepubertal patients. After 4 years of deflazacort treatment, Height standard deviation score for chronological age did not change in 7 prepubertal patients. Mean Weight/Height Ratio decreased by 50% (1st year) and remained reduced during follow-up. Serum IGF-I, IGF binding protein -3 (IGFBP3), IGF/IGFBP3 molar Ratio, and IGF-I and -II binding capacities showed no significant change; however in 5 of 6 patients IGFBP2 decreased during deflazacort therapy. Our findings suggest that immunosuppressive treatment with deflazacort is as effective as methylprednisone and may lead to an improvement in the growth prognosis of children with renal transplantation.

  • effect of therapy with a new glucocorticoid deflazacort on linear growth and growth hormone secretion after renal transplantation
    The Journal of Pediatrics, 1992
    Co-Authors: Jorge R Ferraris, Raul Gutman, E Granillo, Susana Ruiz, José A. Ramírez, Titania Pasqualini
    Abstract:

    Deflazacort is an oxazoline compound derived from prednisolone with similar antiinflammatory effects but fewer side effects. We studied changes in kidney function, growth velocity, Weight/Height Ratio, and growth hormone secretion before and a year after substitution of deflazacort for methylprednisone in nine patients aged 9 to 15 years, 4 years after renal transplantation; all were in Taner pubertal stage 1. Methylprednisone (mean±SEM: 0.2±0.02 mg/kg per day) was replaced by deflazacort (0.3±0.03 mg/kg per day) for a mean period of 15 months. Serum creatinine and calculated creatinine clearance did not change significantly during deflazacort treatment. Growth velocity increased from 1.5±0.3 to 3.2±0.5 cm/yr ( p p p

Hector Jasper - One of the best experts on this subject based on the ideXlab platform.

  • effect of deflazacort versus methylprednisone on growth body composition lipid profile and bone mass after renal transplantation
    Pediatric Nephrology, 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P<0.05) and decreased in deflazacort-treated patients (P<0.005). Lean body mass increased in both groups (P<0.005). Fat body mass and serum leptin increased only in methylprednisone-treated patients (P<0.025). Total cholesterol and low-density lipoprotein-cholesterol increased in methylprednisone-treated patients by 9.9% (P<0.05) and 12.5% (P<0.025). High-density lipoprotein-cholesterol increased by 21% (P<0.005) and apolipoprotein B decreased by 11% (P<0.005) in deflazacort-treated patients. Total skeleton and lumbar spine bone mineral density decreased in both groups, but at 1 year methylprednisone-treated patients had lost 50% more bone. Bone mineral content decreased only in methylprednisone-treated patients (P<0.01). Our data suggest that substituting deflazacort for maintenance methylprednisone might prevent Height loss, excessive bone loss, and fat accumulation; and leads to an improvement in the lipoproteins of these children.

  • effects of deflazacort immunosuppression on long term growth and growth factors after renal transplantation
    Pediatric Nephrology, 1997
    Co-Authors: Jorge R Ferraris, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Deflazacort is an oxazoline compound derived from prednisolone. We studied changes in kidney function, growth velocity, Weight/Height Ratio, insulin-like growth factor (IGF-I), and IGF binding proteins before and after substitution of deflazacort for methylprednisone in 27 transplanted patients aged 3.1 – 20 years. Methylprednisone (mean±SEM 0.17±0.01 mg/kg per day) was replaced by deflazacort (0.29±0.01 mg/kg per day) for a period of 1 – 5 years. Calculated creatinine clearance did not change significantly during deflazacort treatment. Growth velocity increased from 2.6±0.5 cm/year to 5.2±0.7 cm/year (1st year) in 14 prepubertal patients. After 4 years of deflazacort treatment, Height standard deviation score for chronological age did not change in 7 prepubertal patients. Mean Weight/Height Ratio decreased by 50% (1st year) and remained reduced during follow-up. Serum IGF-I, IGF binding protein -3 (IGFBP3), IGF/IGFBP3 molar Ratio, and IGF-I and -II binding capacities showed no significant change; however in 5 of 6 patients IGFBP2 decreased during deflazacort therapy. Our findings suggest that immunosuppressive treatment with deflazacort is as effective as methylprednisone and may lead to an improvement in the growth prognosis of children with renal transplantation.

Patricia Sorroche - One of the best experts on this subject based on the ideXlab platform.

  • effect of deflazacort versus methylprednisone on growth body composition lipid profile and bone mass after renal transplantation
    Pediatric Nephrology, 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P<0.05) and decreased in deflazacort-treated patients (P<0.005). Lean body mass increased in both groups (P<0.005). Fat body mass and serum leptin increased only in methylprednisone-treated patients (P<0.025). Total cholesterol and low-density lipoprotein-cholesterol increased in methylprednisone-treated patients by 9.9% (P<0.05) and 12.5% (P<0.025). High-density lipoprotein-cholesterol increased by 21% (P<0.005) and apolipoprotein B decreased by 11% (P<0.005) in deflazacort-treated patients. Total skeleton and lumbar spine bone mineral density decreased in both groups, but at 1 year methylprednisone-treated patients had lost 50% more bone. Bone mineral content decreased only in methylprednisone-treated patients (P<0.01). Our data suggest that substituting deflazacort for maintenance methylprednisone might prevent Height loss, excessive bone loss, and fat accumulation; and leads to an improvement in the lipoproteins of these children.

  • Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation
    Pediatric nephrology (Berlin Germany), 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Héctor G. Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P

  • Effect of therapy with deflazacort on dyslipoproteinemia after pediatric renal transplantation.
    The Journal of Pediatrics, 1998
    Co-Authors: Jorge R Ferraris, Patricia Sorroche, José Oyhamburu, Pedro Brandi, Titania Pasqualini
    Abstract:

    Deflazacort is an oxazolone compound derived from prednisolone, with similar immunosuppressive action but fewer side effects. Kidney function, Weight/Height Ratio, serum triglycerides, cholesterol, high-density lipoprotein (HDL) cholesterol, very-low-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein A, apolipoprotein B, and lipoprotein (a) were studied before and 6 months after substitution of deflazacort (mean ± SEM, 0.3 ± 0.1 mg/kg per day) for methylprednisone (0.2 ± 0.1 mg/kg per day) in 14 patients treated with cyclosporine, aged 3.1 to 20.3 years, 3 years after renal transplantation. Serum creatinine and calculated creatinine clearance did not change significantly, and Weight/Height Ratio decreased from 20.0% ± 7.1% to 12.5% ± 6.5% (P < .005) during deflazacort therapy. Total cholesterol was reduced by 15.9% (from 233 ± 15 mg/dL to 196 ± 13 mg/dL, P < .01), LDL cholesterol by 25.5% (from 153 ± 14 mg/dL to 114 ± 12 mg/dL, P < .01), and TC/HDL cholesterol Ratio by 28.3% (from 5.3 ± 0.4 to 3.8 ± 0.4, P < .01), whereas HDL cholesterol increased 18% (from 45 ± 2 mg/dL to 53 ± 2 mg/dL) and apolipoprotein A by 8.3% (from 122 ± 5 mg/dL to 132 ± 5 mg/dL, P < .05) during deflazacort therapy. Our data suggest that substituting deflazacort for maintenance methylprednisone therapy leads to an improvement in the lipoprotein profile of children after renal transplantation. (J Pediatr 1998;133:533-6)

Patricia Pennisi - One of the best experts on this subject based on the ideXlab platform.

  • Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation
    Pediatric nephrology (Berlin Germany), 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Héctor G. Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P

  • effect of deflazacort versus methylprednisone on growth body composition lipid profile and bone mass after renal transplantation
    Pediatric Nephrology, 2000
    Co-Authors: Jorge R Ferraris, Horacio M Domene, Patricia Sorroche, A M Galich, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Kidney function, growth velocity, Weight/ Height Ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/Height Ratio was increased in methylprednisone-treated patients (P<0.05) and decreased in deflazacort-treated patients (P<0.005). Lean body mass increased in both groups (P<0.005). Fat body mass and serum leptin increased only in methylprednisone-treated patients (P<0.025). Total cholesterol and low-density lipoprotein-cholesterol increased in methylprednisone-treated patients by 9.9% (P<0.05) and 12.5% (P<0.025). High-density lipoprotein-cholesterol increased by 21% (P<0.005) and apolipoprotein B decreased by 11% (P<0.005) in deflazacort-treated patients. Total skeleton and lumbar spine bone mineral density decreased in both groups, but at 1 year methylprednisone-treated patients had lost 50% more bone. Bone mineral content decreased only in methylprednisone-treated patients (P<0.01). Our data suggest that substituting deflazacort for maintenance methylprednisone might prevent Height loss, excessive bone loss, and fat accumulation; and leads to an improvement in the lipoproteins of these children.

  • effects of deflazacort immunosuppression on long term growth and growth factors after renal transplantation
    Pediatric Nephrology, 1997
    Co-Authors: Jorge R Ferraris, Patricia Pennisi, Titania Pasqualini, Hector Jasper
    Abstract:

    Deflazacort is an oxazoline compound derived from prednisolone. We studied changes in kidney function, growth velocity, Weight/Height Ratio, insulin-like growth factor (IGF-I), and IGF binding proteins before and after substitution of deflazacort for methylprednisone in 27 transplanted patients aged 3.1 – 20 years. Methylprednisone (mean±SEM 0.17±0.01 mg/kg per day) was replaced by deflazacort (0.29±0.01 mg/kg per day) for a period of 1 – 5 years. Calculated creatinine clearance did not change significantly during deflazacort treatment. Growth velocity increased from 2.6±0.5 cm/year to 5.2±0.7 cm/year (1st year) in 14 prepubertal patients. After 4 years of deflazacort treatment, Height standard deviation score for chronological age did not change in 7 prepubertal patients. Mean Weight/Height Ratio decreased by 50% (1st year) and remained reduced during follow-up. Serum IGF-I, IGF binding protein -3 (IGFBP3), IGF/IGFBP3 molar Ratio, and IGF-I and -II binding capacities showed no significant change; however in 5 of 6 patients IGFBP2 decreased during deflazacort therapy. Our findings suggest that immunosuppressive treatment with deflazacort is as effective as methylprednisone and may lead to an improvement in the growth prognosis of children with renal transplantation.